BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.29 -0.58%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Equinor ASA (ADR) (EQNR) to Buy
- Erste Group Upgrades Toyota Motor (TM) to Buy, 'more profitable than its competitors'
- UBS Upgrades Waste Connections Inc. (WCN) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
